Comparative hepatitis C genotype 1-3 viral load kinetics in response to directly-acting antiviral therapy
- 1 May 2020
- journal article
- letter
- Published by Elsevier BV in Journal of Infection
- Vol. 80 (5), 596-598
- https://doi.org/10.1016/j.jinf.2020.01.011
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6.BioMed Research International, 2019
- Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance GroupJournal of Infection, 2019
- Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4–infected patients with advanced liver fibrosis and decompensated cirrhosisJournal of Infection, 2018
- The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?Scientific Reports, 2017
- Oral Direct-Acting Agent Therapy for Hepatitis C Virus InfectionAnnals of Internal Medicine, 2017
- Geno2pheno[HCV] – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsPLOS ONE, 2016
- Antiviral therapies for chronic hepatitis C virus infection with cirrhosisWorld Journal of Hepatology, 2015
- Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agentsJournal of Infection, 2014
- Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C VirusThe Journal of Infectious Diseases, 2000